-
Detailed Analysis Generate Full Report Add to Watchlist
Values as of: 2025-04-01
ARQT:NSD- (USD)
COMMON STOCK | Biotechnology |
Last Closing
USD 14.98Change
-0.66 (-4.22)%Market Cap
USD 1.87BVolume
1.46MVerdict
Verdict
Values as of: 2025-04-01
COMMON STOCK | Biotechnology |
Last Closing
USD 14.98Change
-0.66 (-4.22)%Market Cap
USD 1.87BVolume
1.46MVerdict
Verdict
Currency: USD
Country : USA
Symbol | Name | Price(Change) | Market Cap |
---|---|---|---|
VRTX | Vertex Pharmaceuticals Inc |
N/A |
USD 126.52B |
REGN | Regeneron Pharmaceuticals Inc |
N/A |
USD 69.68B |
ARGX | argenx NV ADR |
N/A |
USD 37.97B |
ALNY | Alnylam Pharmaceuticals Inc |
N/A |
USD 31.94B |
ONC | BeiGene, Ltd. |
N/A |
USD 28.70B |
RPRX | Royalty Pharma Plc |
N/A |
USD 19.31B |
SMMT | Summit Therapeutics PLC |
N/A |
USD 14.57B |
UTHR | United Therapeutics Corporatio.. |
N/A |
USD 14.37B |
INCY | Incyte Corporation |
N/A |
USD 14.22B |
MRNA | Moderna Inc |
N/A |
USD 13.74B |
Symbol | Name | Weight | Mer | Price(Change) | Market Cap |
---|---|---|---|---|---|
PINK | Simplify Exchange Traded .. | 6.72 % | 0.00 % |
N/A |
USD 0.15B |
BBC | Virtus LifeSci Biotech Cl.. | 1.41 % | 0.79 % |
N/A |
USD 0.01B |
FYC | First Trust Small Cap Gro.. | 0.84 % | 0.70 % |
N/A |
USD 0.41B |
FYX | First Trust Small Cap Cor.. | 0.42 % | 0.63 % |
N/A |
USD 0.85B |
Market Performance vs. Industry/Classification (Biotechnology) | Market Performance vs. Exchange | ||||||
Value | Sector Median | Percentile Rank | Grade | Market Median | Percentile Rank | Grade | |
YTD | |||||||
Capital Gain | 7.54% | 85% | B | 84% | B | ||
Dividend Return | N/A | N/A | N/A | N/A | N/A | ||
Total Return | 7.54% | 85% | B | 84% | B | ||
Trailing 12 Months | |||||||
Capital Gain | 59.36% | 92% | A | 92% | A | ||
Dividend Return | N/A | N/A | N/A | N/A | N/A | ||
Total Return | 59.36% | 92% | A | 92% | A | ||
Trailing 5 Years | |||||||
Capital Gain | -42.03% | 62% | D | 25% | F | ||
Dividend Return | N/A | N/A | N/A | N/A | N/A | ||
Total Return | -42.03% | 62% | D | 24% | F | ||
Average Annual (5 Year Horizon) | |||||||
Capital Gain | 6.40% | 58% | F | 57% | F | ||
Dividend Return | 6.40% | 58% | F | 54% | F | ||
Total Return | N/A | N/A | N/A | N/A | N/A | ||
Risk Return Profile | |||||||
Volatility (Standard Deviation) | 105.92% | 35% | F | 19% | F | ||
Risk Adjusted Return | 6.04% | 57% | F | 40% | F | ||
Market Capitalization | 1.87B | 88% | B+ | 79% | B- |
Target Price Action | Rating Action | Analyst | Rating | Price | Date |
---|
This is a composite scorecard based on the application of evaluation criteria deemed most important by analysts. This is not a buy or sell recommendation.
This is one of the largest entities in its sector and is among the top quartile. Such companies tend to be more stable.
This stock is in the top quartile compared to its peers on Gross Profit to Asset Ratio. This is a popular measure among value investors for showing superior returns in the long run.
The company is in the bottom half compared to its sector peers on debt to equity and is highly leveraged. However, do check the news and look at its sector and management statements. Sometimes this is high because the company is trying to grow aggressively.
The stock is trading high compared to its peers median on a price to book value basis.
The total returns for this company are volatile and above median for its sector over the past 5 years. Make sure you have the risk tolerance for investing in such stock.
The company had negative total cash flow in the most recent four quarters.
The company had negative total earnings in the most recent four quarters.
The company had negative total free cash flow in the most recent four quarters.
This stock has shown below median earnings growth in the previous 5 years compared to its sector